PureTech Health PLC Transaction in Own Shares (3186D)
October 19 2022 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 3186D
PureTech Health PLC
19 October 2022
19 October 2022
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has
purchased the following number of its ordinary shares of one pence
each through Jefferies International Limited ("Jefferies"), as part
of its Share Buyback Programme, details of which were announced on
9 May 2022.
Date of purchase: 18 October 2022
Number of ordinary shares purchased: 38
Highest price paid per share: 229.00p
Lowest price paid per share: 229.00p
Volume weighted average price paid per
share: 229.00p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have 8,936,832
ordinary shares in treasury and has 280,124,960 ordinary shares in
issue (excluding treasury shares). The total number of voting
rights in the Company is therefore 280,124,960 , which may be used
by shareholders in their calculations to determine if they are
required to notify their interest in, or a change to their interest
in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No
596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018) (the Market Abuse Regulation),
detailed information about the individual purchases is available
below.
About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the
treatment paradigm for devastating diseases. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 27 therapeutics and therapeutic
candidates, including two that have received both U.S. FDA
clearance and European marketing authorization and a third that is
expected to be filed soon for FDA approval, as of the date of
PureTech's most recently filed Half-Year Report and corresponding
Form 6-K. All of the underlying programs and platforms that
resulted in this pipeline of therapeutic candidates were initially
identified or discovered and then advanced by the PureTech team
through key validation points based on unique insights in
immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Transaction Volume Price Platform Transaction Reference
Date Time (GBp) Number
18/10/2022 09:59:27 26 229 BATE 00322175798TRLO1.1.1
------------ ------- ------- --------- ----------------------
18/10/2022 09:59:08 10 229 AQXE 00322175669TRLO1.1.1
------------ ------- ------- --------- ----------------------
18/10/2022 09:59:07 2 229 AQXE 00322175666TRLO1.1.1
------------ ------- ------- --------- ----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSFLFFRIILTLIF
(END) Dow Jones Newswires
October 19, 2022 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024